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Abstract
Background: IFNγ-producing CD4+CD25+Foxp3+CD127- Treg represent the first line of Treg during an immune
response. In the present study we determined whether IFNγ+ Treg in-vivo and in-vitro are Helios-positive representing
activated natural (nTreg) or Helios-negative representing adaptive Treg (aTreg) and whether they originate from CD4
+CD25+ and/or CD4+CD25- PBL. Furtheron, we investigated whether they are inducible by recombinant IFNγ (rIFNγ)
as a single stimulus, decrease in-vitro after elimination of the stimulus, and have a demethylated Foxp3 Treg-specific
demethylated region (TSDR) which is associated with stable Foxp3 expression.
Method: Subsets of IFNγ+ Treg were determined in peripheral blood of healthy controls using eight-color flow
cytometry and were further investigated in-vitro. Foxp3 TSDR methylation status was determined using bisulphite
polymerase chain reaction (PCR) and high resolution melt (HRM) analysis.
Results: Nearly all Treg in the peripheral blood were Helios+IFNγ- (1.9 ± 1.1/μl) and only few were Helios+IFNγ+ or
Helios-IFNγ+ Treg (both 0.1 ± 0.1/μl). Enriched IFNγ+ Treg subsets showed in part strong Foxp3 TSDR demethylation.
In-vitro, rIFNγ was unable to induce Treg. CD4+CD25+ enriched PBL stimulated with PMA/Ionomycin in the presence
of rIFNγ were rather resistant to the effect of rIFNγ, in contrast to CD4+CD25- enriched PBL which showed increasing
total Treg with Helios+ Treg switching from IFNγ- to IFNγ+ and increasing Helios-IFNγ+ Treg. The data indicate that
rIFNγ, in combination with a polyclonal stimulus, activates nTreg and induces aTreg. When phorbol 12-myristate
13-acetate (PMA)/Ionomycin was washed out from the cell culture after 6 h stimulation, Treg induction continued for
at least 96 h of cell culture, contradicting the hypothesis that removal of the stimulus results in significant decrease of
IFNγ- and IFNγ+ CD4+CD25+Foxp3+CD127- Treg due to loss of Foxp3 expression.
Conclusions: IFNγ+Helios- aTreg as well as IFNγ+Helios+ nTreg are detectable in the blood of healthy individuals,
show in part strong Foxp3 TSDR demethylation and are inducible in-vitro. The present data provide further insight
concerning the in-vivo and in-vitro characteristics of IFNγ+ Treg and help to understand their role in immunoregulation.
Alloantigen-specific demethylated IFNγ+Helios+ nTreg might represent a suitable marker for monitoring graft-specific
immunosuppression in renal transplant recipients.
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Background
T regulator cells (Treg) in the peripheral circulation of
humans are usually IFNγ-. However, during stimulation
CD4+CD25+CD127-Foxp3+ Treg are formed that co-
express IFNγ, as reviewed by Daniel et al. [1]. IFNγ+ Treg
are detectable in the blood of renal transplant recipients
with good long-term graft function and in patients with
autoimmune disease, such as type-1 diabetes and multiple
sclerosis [2–4]. They co-express IFNγ receptors on the cell
surface and are inducible by IFNγ (auto- and paracrine
activation) [5, 6]. In addition to IFNγ, the cells produce
TGFß and/or IL10 and co-express cell surface receptors
that are involved in cell-cell contact inhibition as well as
effector cell killing, such as CD152, CD178, CD95, and
CD279 [6, 7]. Separated CD4+CD25+CD127-IFNγ+ Treg
suppress MLCs unspecifically, although the strongest sup-
pression is observed in antigen-specific mixed lymphocyte
culture (MLC) settings [5, 7, 8]. The stronger the HLA
incompatibility and proliferation in MLC experiments, the
stronger the induction of CD4+CD25+Foxp3+IFNγ+ PBL
[8]. Interestingly, patients with poor long-term allograft
function after renal transplantation are able to form CD4
+CD25+Foxp3+IFNγ+ PBL in MLC with pretransplant
obtained peripheral blood lymphocytes (PBL) [8]. How-
ever, posttransplant these patients showed lower frequen-
cies of these cells in the periphery than renal transplant
recipients with good long-term graft outcome [2]. This
finding suggests that patients with poor long-term graft
outcome did not develop or lost this particular Treg
subset posttransplant, perhaps because of intensified im-
munosuppressive treatment. The in-vitro behavior of
IFNγ+CD4+CD25+Foxp3+CD127- Treg suggests that
they form the first line of Treg, patrolling in the body and
searching for IFNγ and initial immune responses that they
subsequently suppress.
Origin and stability of suppressive function of IFNγ+
Treg are important factors with respect to the clinical
relevance of this Treg subset [1]. Usually, the Foxp3 Treg-
specific demethylated region (TSDR) of Tregs is demethy-
lated, whereas that of conventional T cells is methylated
[9, 10]. TSDR methylation persists during transient ex-
pression of Foxp3 by convential T cells or unstable TGFß-
induced Treg, whereas drug-induced demethylation of
conventional T cells results in stable Foxp3 expression,
suggesting that lineage stability in Treg may be epigeneti-
cally regulated. Signaling through IFNγR and IL12R, in
combination with T cell receptor (TCR) engagement, in-
duces strong expression of the transcription factor T-bet,
which drives the differentiation of conventional T cells to
a T helper type 1 (Th1) lineage [11]. The Ikaros family
transcription factor Helios has been shown to be select-
ively expressed in nTreg of thymic origin but not in per-
ipherally induced aTreg [12]. McClymont et al. reported
that the majority of in-vitro induced IFNγ+ Tregs did not
express Helios, suggesting that they were generated extra-
thymically [4]. Alternatively, they might belong to a mi-
nority of Helios- nTreg with demethylated TSDR express-
ing Foxp3, CD39, CTLA-4, CCL3 and IFNγ, as published
by Himmel et al. [13]. Further experiments showed that
nTreg can polarize towards IFNγ+ T cells in-vitro by IL12
conditioning whereby they remain Helios+, suggesting
that part of the thymic-derived Treg population exhibits
plasticity in cytokine production and expresses a Th1-like
phenotype [4]. Hall et al. reported that rat nTreg stimu-
lated with antigen and IFNγ or IL12 expand and differen-
tiate to antigen-specific IFNγ+ nTreg that have a 100- to
1000-fold increased suppressor potency as compared to
nTreg [14, 15]. This strongly potent antigen-specific
nTreg subset with a Th1-like phenotype might represent a
suitable marker for monitoring graft-specific immunosup-
pression in renal transplant recipients.
In the present study we examined the origin of IFNγ+
Treg as determined by Helios positivity in peripheral
blood and PMA/Ionomycin-stimulated cell cultures per-
formed with PBL from healthy individuals. Furtheron,
we investigated whether IFNγ+ Treg can be induced by
recombinant IFNγ (rIFNγ) without additional stimulus
and whether IFNγ+ Treg after removal of the stimulus
remain IFNγ+Foxp3+ or, alternatively, decrease and dif-
ferentiate to IFNγ+Foxp3- Th1 and/or IFNγ-Foxp3+
Treg. Based on findings in mouse experiments, Feng et
al. reported that in-vitro induced IFNγ+ Treg suppress
inflammation effectively when transferred to mice with
colitis but differentiate to Th1 lymphocytes when adop-
tively transferred to mice without inflammation [16]. Fi-
nally, we determined the Foxp3 TSDR demethylation
status of separated IFNγ+ Treg in order to assess stabil-
ity of Foxp3 expression.
Results
Treg subsets in peripheral blood of healthy controls
Figure 1 demonstrates the gating strategy. Figure 2 depicts
Treg subset numbers in the blood of 12 healthy indi-
viduals. Mean ± SEM (range) of circulating CD4+ PBL
was 799 ± 220/μl (483–1179/μl) and of circulating
CD4+CD25+Foxp3+CD127- Treg 3.0 ± 1.4/μl (1.2–6.4/μl).
Approximately two-thirds of all Treg expressed the
classical nTreg phenotype Helios+IFNγ- (1.9 ± 1.1/μl;
0.7–3.7/μl). In contrast, only a small minority of Treg
produced IFNγ and was Helios+IFNγ+ (0.1 ± 0.1/μl; 0–
0.4/μl) or Helios-IFNγ+ (0.1 ± 0.1/μl; 0–0.5/μl). Half of
IFNγ+ Treg appear to originate from the thymus (Hel-
ios+) and represent activated nTreg, whereas the other
half appear to be induced in the periphery (Helios-) and
represent aTreg. CD4+CD25+Foxp3+CD127- Treg were
found to express TGFß, CD62L, CXCR3, CD152, Perforin,
Granzyme B, CD28, HLA-DR, CD95, CD178, CD154,
Tbet and IFNγR1 CD119. The data suggest that IFNγ+
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Treg have the potential to enter secondary lymphoid or-
gans as well as inflamed tissues (CD62L, CXCR3) and are
able to induce suppression of immune responses either by
apoptosis (CD95, CD178), cell death (Perforin, Granzyme
B), cytokine secretion (TGFß) or cell-cell interaction
(CD152, CD154). Moreover, they have the potency to
regulate production as well as consumption of IFNγ in the
cell by surface receptors (CD119) and induction of tran-
scription factors (Tbet). Interestingly, IL10+ Treg pheno-
types were undetectable in the circulation whereas TGFß+
IFNγ+ Treg were rather frequent (Fig. 2).
Cell cultures stimulated with rIFNγ only
As shown previously, IFNγ+ Treg express IFNγ receptors
[6]. We hypothesized that IFNγ+ Treg might be inducible
by recombinant rIFNγ without additional stimulus. When
unseparated PBL of 4 healthy volunteers were stimulated
with 500 or 1000 ng/ml rIFNγ for 24 and 48 h, there was
no statistically significant increase in any of the Treg
subsets depicted in Fig. 3 (24 h resp. 48 h: 0 ng/ml vs
500 ng/ml resp. 1000 ng/ml rIFNγ, p = n.s.). Rather, there
was a decrease of CXCR3+CD62L+ (48 h: 0 ng/ml vs
500 ng/ml resp. 1000 ng/ml rIFNγ, both p = 0.029) as well
as CD152+CD154+ (48 h: 0 ng/ml vs 1000 ng/ml rIFNγ,
p = 0.029) Treg. The data suggest that rIFNγ is unable to
induce Treg, especially IFNγ+ Treg, in the absence of an
additional stimulus.
IFNγ+ Treg induced in-vitro in the presence of both rIFNγ
and PMA/Ionomycin
We speculated that rIFNγ might induce IFNγ+ Treg
only in combination with an additional stimulus, such
as PMA/Ionomycin, and that activated nTreg with
Helios+IFNγ+ phenotype originate mainly from the
CD4+CD25+ PBL preparation. We therefore investi-
gated the induction of IFNγ+ Treg in cell cultures with
unseparated PBL, enriched CD4+CD25+ and enriched
CD4+CD25- PBL preparations. CD4+ PBL were enriched
to 99 ± 0.6 % purity. CD4+CD25+ enriched PBL fractions
contained 87 ± 9.9 % and the remaining CD4+CD25- PBL
preparation 33 ± 10.6 % CD4+CD25+ PBL. PBL prepara-
tions of 5 healthy individuals were stimulated for 72 h
with PMA/Ionomycin in the presence of 500 ng/ml,
1000 ng/ml, 5000 ng/ml or without rIFNγ.
Unseparated PBL
Stimulation of unseparated PBL with PMA/Ionomycin
alone for 24 h increased the proportions of total CD4
+CD25+Foxp3+CD127- (24 h: with vs without PMA/
Iono: p = 0.056) and Helios-IFNγ+ (p = 0.008) Treg,
but decreased the proportion of Helios+IFNγ-IL10-
TGFß+ (p = 0.056) Treg (Fig. 4a). Addition of rIFNγ to
PMA/Ionomycin-stimulated cell cultures decreased the
proportions of Helios+IFNγ- (24 h resp. 48 h: PMA/
Iono vs PMA/Iono + 5000 ng/ml rIFNγ, p = 0.016 resp.
p = 0.008) and Helios+IFNγ-IL10-TGFß+ (48 h: PMA/
(See figure on previous page.)
Fig. 1 Determination of Treg subsets. a Total CD4+ lymphocytes of a healthy individual were gated (gate P2) and further analysed concerning
intracellular Helios and IFNγ positivity. The majority of circulating CD4+ lymphocytes was Helios- and this gate was used for all further flow
cytometric analyses of Helios positivity. b Stepwise gating strategy for Treg subset determination: first, lymphocytes gate (P1), then CD4+CD25+ PBL
gate (P2), Foxp3+CD127- gate (P3), and finally Helios/IFNγ gate. Further CD4+CD25+Foxp3+CD127- Treg subsets (based on gate P3) were analysed
using the depicted gate settings for IL10/TGFß, CXCR3/CD62L, CD252/CD152 (CD152 intracellular), CD119/Tbet, CD28/HLA-DR, CD152/CD154 (both
surface), Perforin/GranzymeB, and CD95/CD178
Fig. 2 Absolute counts of different CD4+CD25+Foxp3+CD127- Treg subsets in the blood of 12 healthy controls. Two-thirds of all CD4+CD25+Foxp3
+CD127- Treg were Helios+IFNγ- nTreg, only a small minority represents Helios+IFNγ+ activated nTreg or Helios-IFNγ+ peripherally induced aTreg. The
additionally investigated parameters give insight into the immunosuppressive armamentarium and the mechanisms of IFNγ+ Treg function. Data are
given as mean ± SEM
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Iono vs PMA/Iono + 500 resp. 1000 resp. 5000 ng/ml
rIFNγ, p = 0.016 resp. p = 0.008 resp. p = 0.008) Treg and
increased the proportion of Helios-IFNγ+ (24 h: PMA/
Iono vs PMA/Iono + 5000 ng/ml rIFNγ, p = 0.032) Treg. It
appears that rIFNγ decreased the Helios+IFNγ- and in-
creased the Helios-IFNγ+ Treg subset in PMA/Ionomycin-
stimulated cell cultures.
Enriched CD4+CD25+ PBL
When, instead of unseparated PBL, cell preparations
enriched for CD4+CD25+ PBL were stimulated, addition
of rIFNγ increased Helios-IFNγ+ (24 h: PMA/Iono vs
PMA/Iono + 500 ng/ml rIFNγ, p = 0.056) Treg. Helios
+IFNγ+ Treg decreased (48 h: PMA/Iono vs PMA/Iono +
500 ng/ml rIFNγ; p = 0.056) but tended to increase in the
presence of higher rIFNγ concentrations in the culture
medium (p = n.s.) (Fig. 4b).
Enriched CD4+CD25- PBL
Stimulation of enriched CD4+CD25- PBL with PMA/Iono-
mycin alone increased total CD4+CD25+Foxp3+CD127-
(24 h: with vs without PMA/Iono: p = 0.016) and Helios
+IFNγ- (p = 0.056) as well as Helios+IFNγ+ (p = 0.056)
Treg (Fig. 4c). When rIFNγ was added to PMA/Ionomy-
cin-stimulated cell cultures, a decrease of Helios+IFNγ-
Treg was noted (24 h: PMA/Iono vs PMA/Iono + 1000
resp. 5000 ng/ml rIFNγ, p = 0.056 resp. p = 0.008; 48 h:
PMA/Iono vs PMA/Iono + 1000 resp. 5000 ng/ml rIFNγ,
p = 0.032 resp. p = 0.008) as well as of Helios+IFNγ-IL10-
TGFß+ (48 h: PMA/Iono vs PMA/Iono + 1000 resp.
5000 ng/ml rIFNγ, p = 0.008 resp. p = 0.008), whereas
Helios-IFNγ+ (48 h: PMA/Iono vs PMA/Iono + 1000 resp.
5000 ng/ml rIFNγ, p = 0.032 resp. p = 0.032) Treg in-
creased. A strong increase of total CD4+CD25+Foxp3
+CD127- (p = 0.008) and Helios+IFNγ+ (p = 0.016) Treg as
well as an increase of Helios-IFNγ+ (p = 0.056) Treg was
observed when freshly separated CD4+CD25- PBL were
compared with CD4+CD25- PBL after 24 h stimulation
with PMA/Ionomycin.
The data suggest that rIFNγ in combination with PMA/
Ionomycin decreases Helios+IFNγ- and increases Helios-
IFNγ+ Treg in-vitro and that this effect was more pro-
nounced in cell cultures with enriched CD4+CD25- than
in cell cultures with CD4+CD25+ PBL. Treatment with
rIFNγ appears to increase total Treg that are Helios-
IFNγ+ and induces a switch of Helios+ Treg from IFNγ-
to IFNγ+. We conclude that rIFNγ in combination with a
polyclonal stimulus induces aTreg and activates nTreg.
Kinetics of Treg subsets in-vitro in culture of CD4+CD25+
or CD4+CD25- PBL preparations after elimination of the
stimulus
Next, we studied the fate of Treg subsets after removal of
a short-term polyclonal stimulus. CD4+CD25+ enriched
(82 ± 15 % CD4+CD25+ PBL) and CD4+CD25+ depleted
(33 ± 5.3 % CD4+CD25+ PBL) cell preparations as well as
unseparated PBL from 3 healthy individuals were stimu-
lated with PMA/Ionomycin for 6 h. PMA/Ionomycin was
washed out of the cell culture and Treg subsets were ana-
lyzed again at 7, 24, 72 and 96 h. In PBL cell cultures, total
CD4+CD25+Foxp3+CD127- (7 h vs 72 h, p = 0.029) and
Helios+IFNγ+ (7 h vs 72 h, p = 0.045) Treg increased after
Fig. 3 Cell cultures stimulated with rIFNγ only. Unseparated PBL of 4 healthy individuals were cultured for 48 h in the presence of 500 ng/ml,
1000 ng/ml or without rIFNγ. There was no significant increase of IFNγ+CD4+CD25+Foxp3+CD127- Treg during the culture period (24 h resp.
48 h: 0 ng/ml vs 500 ng/ml resp. 1000 ng/ml, p = n.s.). The data suggest that rIFNγ is unable to induce Treg, especially IFNγ+CD4+CD25+Foxp3
+CD127- Treg, without an additional stimulus. Rather, there was a decrease of CXCR3+CD62L+ (48 h: 0 ng/ml vs 500 ng/ml resp. 1000 ng/ml
rIFNγ, both p = 0.029) as well as CD152+CD154+ (48 h: 0 ng/ml vs 1000 ng/ml rIFNγ, p = 0.029) Treg. Data are given as mean ± SEM. *p≤ 0.05;
**p≤ 0.01; ***p≤ 0.001
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Fig. 4 IFNγ+ Treg induced in-vitro in the presence of both rIFNγ and PMA/Ionomycin. a PBL of 5 healthy individuals were stimulated for 72 h using
PMA/Ionomycin in the presence of 500, 1000, 5000 ng/ml or without rIFNγ. PMA/Ionomycin-stimulated cultures without rIFNγ were compared with
those stimulated in the presence of rIFNγ. b, c The same assay was performed using cell cultures with enriched CD4+CD25+ or enriched
CD4+CD25- PBL. The data suggest that CD4+CD25+ PBL are rather resistant to the effect of rIFNγ. In contrast, CD4+CD25- enriched PBL
showed increasing total Treg with both Helios+ Treg switching from IFNγ- to IFNγ+ and increasing IFNγ+Helios- Treg indicating that rIFNγ
in combination with a polyclonal stimulus induces activation of nTreg as well as induction of aTreg. Data are given as mean ± SEM. *p ≤
0.05; **p ≤ 0.01; ***p ≤ 0.001
Fig. 5 Kinetics of Treg subsets induced in-vitro from CD4+CD25+ or CD4+CD25- PBL preparations after elimination of the stimulus. Unseparated as
well as enriched CD4+CD25+ and CD4+CD25- cell preparations were stimulated with PMA/Ionomycin for 6 h and Treg subsets were determined.
Mitogen was removed by several washes of the cell culture and Treg subsets were determined again immediately after the washes at 7 h and at 24,
48, 72 and 96 h after initiation of the cell culture. Assays were performed with PBL from 3 healthy volunteers. The measurement 96 h after initiation of
the cell culture was performed with only one cell donor. CD4+CD25+Foxp3+CD127- Treg increased after removal of the stimulus. The strong increase
of CD4+CD25+Foxp3+CD127- Treg was also observed when instead of unseparated PBL CD4+CD25- enriched PBL fractions were used. In
contrast, CD4+CD25+ enriched PBL fractions showed only an increase of Helios-IFNγ+ Treg. Our data do not support the hypothesis that
removal of the stimulus results in a significant decrease of IFNγ- as well as IFNγ+ CD4+CD25+Foxp3+CD127- Treg due to loss of Foxp3 expression.
Data are given as mean ± SEM. *p≤ 0.05; **p≤ 0.01; ***p≤ 0.001
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removal of the stimulus (Fig. 5a). An increase of CD4
+CD25+Foxp3+CD127- (7 h vs 48 h resp. 72 h, p = 0.053
resp. p = 0.047) was also observed when CD4+CD25-
enriched PBL fractions were studied instead of unseparated
PBL (Fig. 5c). In contrast, CD4+CD25+ enriched PBL frac-
tions showed only an increase of Helios-IFNγ+ Treg (7 h vs
72 h, p = 0.034) (Fig. 5b). Our data do not support the hy-
pothesis [17–24] that removal of the stimulus results in a
significant decrease of IFNγ- as well as IFNγ+ CD4+CD25
+Foxp3+CD127- Treg due to loss of Foxp3 expression. We
found that Helios+ as well as Helios- IFNγ+ Treg increased
during the 96 h observation period.
Foxp3 TSDR DNA methylation status of IFNγ+ and
IFNγ- Treg preparations
Because IFNγ+ CD4+CD25+Foxp3+CD127- Treg are
nearly undetectable in the blood of healthy controls, IFNγ+
Treg were purified by sequential enrichment of CD4+,
CD25+, CD127- and IFNγ+ PBL resulting in CD4+CD25
+CD127-IFNγ+ and CD4+CD25+CD127-IFNγ- Treg
preparations (Fig. 6a). Cell preparations (n = 5) enriched of
IFNγ+ PBL had higher Helios-IFNγ+ (p = 0.043) Treg.
Foxp3 TSDR DNA methylation was analyzed in
enriched CD4+CD25+CD127-IFNγ+ and CD4+CD25
+CD127-IFNγ- Treg preparations from 12 healthy individ-
uals. Figure 6b + c shows the melt curves obtained with
CD4+CD25+CD127-IFNγ+ Treg fractions, Fig. 6d + e the
melt curves obtained with CD4+CD25+CD127-IFNγ-
Treg preparations. 7 of the 12 CD4+CD25+CD127-IFNγ+
and 8 of the 12 CD4+CD25+CD127-IFNγ- Treg prepara-
tions showed partial Foxp3 TSDR methylation of <50 %
and 3 of the CD4+CD25+CD127-IFNγ+ and 2 of the CD4
+CD25+CD127-IFNγ- Treg preparations exhibited a very
low Foxp3 TSDR methylation of <10 %, suggesting that
IFNγ+ and IFNγ- Treg preparations show similar patterns
of demethylated Foxp3 TSDR. It appears that part of
IFNγ+ Treg have stable Foxp3 expression and might rep-
resent activated nTreg.
Discussion
We studied frequencies of IFNγ+ Treg subsets in the per-
ipheral blood of healthy individuals and investigated
whether IFNγ+ Treg originate from Helios+ CD4+CD25+
thymus-derived nTreg and might represent activated
nTreg with Foxp3 TSDR demethylation, stable Foxp3
expression and strong suppressive potency, or, alterna-
tively, differentiate peripherally from Helios- CD4+CD25-
conventional T lymphocytes representing aTreg with
Foxp3 TSDR methylation, transient expression of Foxp3
and low suppressive capacity [1].
Our data indicate that healthy individuals have both
types of IFNγ+ Treg in the blood and that both cell
types co-express determinants characteristic for Treg.
However, only very few IFNγ+ Treg in the blood can be
separated with respect to Helios positivity into activated
nTreg and aTreg. Few of IFNγ+ as well as IFNγ- Treg
preparations showed strong demethylation of Foxp3
TSDR, supporting the hypothesis that part of IFNγ+ Treg
represent activated nTreg. As shown by Hall et al. in rats,
activated nTreg form after stimulation with alloantigen in
the presence of IFNγ or IL12 and express a Th1-like
phenotype [14, 15]. They have a 100- to 1000-fold
increased suppressor potency over nTreg that were gener-
ated by antigen unspecific stimulation with IL2 alone.
These alloantigen-specific IFNγ+ nTreg, formed and
activated in the presence of IFNγ, might be suitable candi-
dates for Treg monitoring in organ-grafted patients. An
increase of this particular Treg subset might indicate
suppression of the graft-specific immune response. In a
previous study, we were able to show that renal transplant
recipients with good long-term graft function possessed
higher proportions of IFNγ+ Treg than patients with im-
paired long-term graft function [2]. Helios positivity and
Foxp3 TSDR methylation status of IFNγ+ Treg were not
determined in that study.
Our current in-vitro data show that IFNγ alone is un-
able to induce this Th1-like Treg subset. However, IFNγ
in combination with a second stimulus amplifies the ac-
tivation of nTreg switching from IFNγ- to IFNγ+, and,
in addition, induces the differentiation of IFNγ+ aTreg.
This observation supports our hypothesis that IFNγ+ Treg
represent the first line of Treg during an immune re-
sponse. However, what is the fate of IFNγ+ Treg when the
immune response is stopped? Do they become apoptotic
or do they further differentiate to Th1 lymphocytes,
losing their Foxp3 expression and forming potentially
harmful graft-specific Th1 lymphocytes? Our data show
that during 90 h after elimination of the polyclonal
(See figure on previous page.)
Fig. 6 Treg subsets and Foxp3 TSDR DNA methylation analysis in enriched CD4+CD25+CD127-IFNγ+PBL preparations. a CD4+CD25+CD127-IFNγ+ Treg
were separated from CD4+CD25+CD127-IFNγ- Treg using PBL from 5 different healthy volunteers. CD4+CD25+Foxp3+CD127- co-expressing Helios-IFNγ+
were significantly enriched in the IFNγ+ Treg preparation whereas CD95+CD178- Treg were depleted compared to IFNγ- Treg preparations. Data are given
as mean ± SEM. *p ≤ 0.05. b-d Foxp3 TSDR DNA methylation analysis of enriched CD4+CD25+CD127-IFNγ+ (b, c) and enriched CD4+CD25
+CD127-IFNγ- (d, e) Treg fractions from 12 healthy individuals (samples 1 – 12). Figure b and d and Fig. c and e correspond with each
other showing test results of the same individuals. In addition, melt curves of the standards with 0, 10, 50 and 100 % methylated Foxp3
TSDR DNA are depicted in each diagram. 4 of 6 IFNγ+ Treg preparations in Fig. 6b, 3 of 6 IFNγ+ Treg preparations in (c), 3 of 6 IFNγ- Treg preparations
in (d) and 5 of 6 IFNγ- Treg preparations in (e) showed a Foxp3 TSDR methylation of <50 % representing mainly demethylated Treg with stable
Foxp3 expression
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stimulus from the cell culture, both IFNγ+ nTreg and
IFNγ+ aTreg continue to increase. Feng et al. reported
that in-vitro induced murine IFNγ+ Treg suppress inflam-
mation effectively when transferred to mice with colitis,
but differentiate to Th1 lymphocytes when adoptively
transferred to mice without inflammation [16]. IFNγ+
Treg that were exposed to an IFNγ-containing milieu dur-
ing our in-vitro experiments or after transfer into inflamed
tissues during the in-vivo experiments of Feng et al. [16]
remained phenotypically and functionally stable. Based on
the experiments of Feng et al. [16], we speculate that
IFNγ+ Treg, when not stimulated further by IFNγ, remain
as resting harmless nTreg or Foxp3-IFNγ- Th1 lympho-
cytes that do not attack the graft in a transplant recipient.
We believe that in stable transplant recipients the lack of
IL12 and IFNγ in the in-vivo milieu might render these
per se graft-specific cells, which differentiated from Th1-
like Treg to Th1 lymphocytes, harmless.
As shown in the blood of healthy individuals, Helios
+IFNγ+ Treg co-express TGFß but not IL10. Further
analysis of Treg phenotypes showed that Treg co-
expressed, in-addition, Granzyme B and Perforin as well
as Fas (CD95) and FasL (CD178), thereby affording the
Treg the capacity to induce lysis and apoptosis of target
cells [6]. Moreover, expression of CTLA-4 (CD152) and
CD40L (CD154) imply cell-cell contact-dependent im-
munosuppression by these Treg subsets. CXCR3 and
CD62L expression suggests that part of these cells have the
potential to enter secondary lymphoid organs as well as
inflamed tissues [25, 26]. These Treg exhibit Th1 charac-
teristic properties such as IFNγR1 (CD119) and Tbet ex-
pression, which means they have the potency to regulate
expression as well as consumption of IFNγ in the cell.
CD28 is involved in Treg activation and HLA-DR expres-
sion indicates activation of Treg [27]. Our present experi-
ments show that these cell markers are expressed on
IFNγ+ as well as IFNγ- Treg in the peripheral blood
(frequency of each subset: <10 % of CD4+CD25+Foxp3
+CD127- Treg; data not shown) and this observation con-
firms the results of our previously published in-vitro stud-
ies [6, 7]. Expression of TGF, CD183, CD62L, CD152,
CD28, CD178, CD95, CD119, T-bet, HLA-DR, Perforin
and Granzyme B in/on circulating CD4+CD25+Foxp3
+CD127- Treg provides insight into the immunosuppres-
sive armamentarium and the mechanisms of IFNγ+ Treg
function. Selection of the most appropriate Treg popula-
tion for cell therapy is a critical step in ensuring successful
clinical outcomes, as reviewed recently [28].
Conclusions
In the blood of healthy individuals, two-thirds of all CD4
+CD25+Foxp3+CD127- Treg were found to be Helios
+IFNγ- nTreg. Only a small minority represents Helios
+IFNγ+ activated nTreg or Helios-IFNγ+ peripherally
induced aTreg. Both IFNγ+ and IFNγ- Treg prepara-
tions contain in part strongly demethylated Foxp3
TSDRs, indicating stable Foxp3 expression characteris-
tic for nTreg. During polyclonal stimulation in the
presence of rIFNγ, Helios-IFNγ+ aTreg are induced and
resting Helios+IFNγ- nTreg differentiate to activated
Helios+IFNγ+ thymically-derived nTreg. rIFNγ alone is
unable to induce this differentiation. Polyclonal activation
induces the expression of IFNγR1 (CD119) and these
receptors are necessary for the stimulating effect of auto-
and paracrine secreted IFNγ. CD119 is expressed on
IFNγ+, IFNγ-, Helios+ as well as Helios- Treg. The fre-
quency of each subset in the peripheral blood was <5 % of
CD4+CD25+Foxp3+CD127- Treg (data not shown). The
present data provide further insight into the in-vivo and
in-vitro characteristics of IFNγ+ Treg and help to under-
stand their role in immunoregulation. Alloantigen-specific
demethylated IFNγ+ Helios+ nTreg might represent a
suitable marker for monitoring graft-specific immunosup-
pression in renal transplant recipients.
Methods
Healthy controls
Laboratory staff served as healthy controls. All controls
gave informed consent for the tests performed within this
study. The study was reviewed by the ethics committee
of the University of Heidelberg and was performed in
accordance with the ethical standards laid down in the
2000 Declaration of Helsinki as well as the Declaration of
Istanbul 2008. All healthy individuals gave their informed
consent prior to their inclusion in the study.
Stimulation of PBL using PMA/Ionomycin
PBL were separated from heparinized or EDTA whole
blood by Ficoll densitiy gradient centrifugation and stimu-
lated for different time intervals using a mixture of phorbol
12-myristate 13-acetate (PMA; final concentration in
medium: 10 ng/ml; Sigma Aldrich, Munich, Germany) and
ionomycin (1 μg/ml; Sigma Aldrich, Munich, Germany) in
RPMI medium containing 10 % FCS, L-Glutamin, and
Penicillin/ Streptomycin (all from Invitrogen Gibco,
Paisley, Scotland) as described previously [5].
Determination of different PBL subsets
PBL subsets were determined as described previously [2,
5]. For analysis of determinants on the cell surface, PBL
were incubated with fluorochrome-labelled monoclonal
antibodies against CD3, CD4, CD25, CD28, CD62L, CD95,
CD119, CD127, CD152, CD154, CD178, CD252, HLA-DR,
and CD183 (CXCR3) (all from BD Biosciences). Intracellu-
lar determinants were stained with fluorochrome-labelled
monoclonal antibodies against Foxp3, IFNγ (clone B27),
IL4, IL10, Granzyme B, Perforin, T-bet (all from BD
Biosciences), Helios (ebioscience, Frankfurt, Germany)
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and TGFß1 (R&D systems, Wiesbaden). Briefly, PBL were
incubated with combinations of monoclonal antibodies for
30 min as described and eight-color fluorescence was ana-
lyzed using a FACSCanto II triple-laser flow cytometer (BD
Biosciences) [2, 5]. When, in addition, intracellular proteins
were studied, cell membranes were permeabilized using BD
Perm/Wash buffer (BD Biosciences). At least 100,000
events were analyzed in the initial FSC/SSC dot plot. IFNγ
monoclonal antibody used for cell separation (BD clone
4S.B3) and IFNγ monoclonal antibody used for cell staining
(BD clone B27) were not competitive (data not shown).
Enrichment of CD4+CD25+CD127-IFNγ+ Treg
Using this procedure, CD4+CD25+CD127-IFNγ+ Treg
were enriched by >80 %. CD4+ and CD25+ PBL were sub-
sequently separated by positive selection using Strep-
Tactin magnetic Microbeads (IBA, Göttingen, Germany)
according to the instructions of the manufacturer. Briefly,
4 μl Fab-Strep were mixed with 1 μl Buffer IS. Then, 15 μl
from the homogeneously resuspended Strep-Tactin Mag-
netic Microbeads were added to the Fab-Strep solution
and incubated overnight at 4 °C. The pre-incubated Fab-
Strep Microbead preparation was added to the cells and
mixed gently for 20 min at 4 °C. Then, 5 ml of buffer IS
were added to the cell/bead preparation. Magnetically
labelled cells were separated by placing the tube for 3 min
onto the StrepMan magnet. Negative cell fraction was
removed with the supernatant whereas the positive cell
fraction was flushed off the tube by resuspension in 5 ml
buffer IS. Magnetic selection was repeated twice. Labelled
cells were resuspended in 10 ml of a 1 mM D-biotin
working solution and incubated for 10 min at room
temperature. Then, tube was placed on the StrepMan
magnet for 3 min and supernatant containing the target
cell fraction was pipetted off the tube and transferred
to another tube. The last step was repeated twice. Cells
were centrifuged by 400 g for 10 min and resuspended
in buffer. Using this procedure, CD4+ and CD25+ PBL
were enriched. Then, CD127- PBL were separated by
negative selection and IFNγ+ PBL were separated by
subsequent positive selection, as described previously
[7]. First, cells were incubated with CD127 monoclonal
antibody (BD Biosciences, Heidelberg, Germany). Then,
CD4+CD25+CD127− were separated from CD4+CD25
+CD127− using streptavidin-coupled beads (Dynabeads
Biotin Binder, Invitrogen, Dynal Oslo, Norway) according
to the instructions of the manufacturer. Procedure was re-
peated using IFNγ monoclonal antibody (BD Biosciences,
Heidelberg, Germany, IFNγ clone 4S.B3). Separated PBL
were added to cell cultures.
DNA isolation
Genomic DNA of separated CD4+CD25+CD127-INFγ+
and CD4+CD25+CD127-INFγ- T cells was extracted using
the QIAamp cultured cells Mini Kit (Qiagen, Hilden,
Germany) according to the protocol of the manufacturer.
DNA was stored in Eppendorf tubes (Eppendorf, Ham-
burg, Germany) at −20 °C.
Bisulfite conversion of genomic DNA
Bisulfite converts unmethylated cytosines to uracil,
whereas methylated cytosines remain unreactive. After
conversion of unmethylated cytosines to uracil by bisul-
fite treatment and subsequent PCR-mediated conversion
of uracils to thymine, methylated and unmethylated
alleles are predicted to differ in thermal stability because
of their different CpG contents. Bisulfite conversion of
genomic DNA was performed using the EZ DNA Methy-
lation Kit (Zymo research, Freiburg, Germany) accord-
ing to the manufacturer’s instructions. CT Conversion
Reagent powder was solved with 750 μl water and
210 μl M-Dilution buffer. 5 μl of M-Dilution buffer was
added to the isolated DNA samples. Total volume was
adjusted to 50 μl with water and mixed. CT Conversion
Reagent and DNA samples were incubated separately in
the dark at 37 °C for 15 min. After incubation, 100 μl
of CT Conversion Reagent was added to each DNA
sample. Samples were mixed and incubated in the dark
at 50 °C for 12–16 h. After incubation DNA samples
were placed on ice for at least 10 min. Then, DNA sam-
ples were loaded into a Zymo-Spin IC Column contain-
ing 400 μl M-Binding buffer, mixed, and centrifuged at
10 000 g for 30 s. Additional 100 μl of M-Wash buffer
were added to the column and centrifuged at 10 000 g
for 30 s. Then, another 200 μl of M-Desulphonation
buffer were added to the column, incubated at room
temperature for 20 min and, finally, centrifuged at 10
000 g for 30 s. Further, 200 μl of M-Wash buffer were
added to the column and centrifuged at 10 000 g for
30 s. The procedure was repeated. Thereafter, the
Zymo-Spin IC Column was placed into a clean 1.5 ml
microcentrifuge tube (Eppendorf ), 15 μl of M-Elution
buffer were added to the column matrix, and samples
were centrifuged at 10 000 g for 30 s. DNA was eluted
in Eppendorf tubes and stored at −20 °C for later use.
Foxp3 TSDR DNA methylation analysis
HRM analysis after bisulfite treatment identifies methy-
lation variations in the Foxp3 gene. Bisulfite modified
DNA was subjected to PCR according to the protocol
for HRM analysis provided by the primer manufacturer
(EpigenDx, Hopkinton, MA, USA). ADS3576 primers
were used for the amplification of the promoter and
5’UTR region, and ADS783 primers for the amplification
of the intron 1 TSDR of the Foxp3 gene. PCR was car-
ried out in a 21 μl total volume containing: 2.1 μl PCR
buffer, 0.27 μl MgCl2, 0.42 μl dNTPs, 1.05 μl SYBR
Green dye (EpigenDx), 1.26 μl each of primers ADS783
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and ADS3576 (Human Foxp3 Methylation Panel, Epi-
genDx), 0.12 μl Hot Start Taq polymerase (Qiagen), and
1.5 μl of bisulfite-treated genomic DNA (concentration
5 ng/μl). The amplification protocol with ADS783 primers
consisted of incubation at 95 °C for 15 min followed by
45 cycles at 95 °C for 30 s, 62 °C for 30 s and 72 °C for
30 s with a final extension step at 72 °C for 5 min. The
amplification protocol with ADS3576 primer consisted of
an incubation at 95 °C for 15 min followed by 45 cycles at
95 °C for 30 s, 59 °C for 30 s and 72 °C for 30 s with a final
extension step at 72 °C for 5 min. Melting was performed
from 60 to 90 °C at a melt rate of 1 %. Each sample was
analyzed in triplicate. DNA methylation analysis and
diagram generation were performed using real-time
PCR software (Applied Biosystems 7500, Foster City,
CA, USA).
Standard curve
7 commercially available standards with different propor-
tions of methylated Foxp3 template DNA were used to es-
timate methylation status of the samples (0, 5, 10, 25, 50,
75, and 100 %) (Human Methylation Controls – Mix,
EpigenDx). Templates were pretreated with bisulfite. For
clarity, only 4 standards are depicted in the figures.
Statistics
All assays were repeated at least 3 times with PBL of
different healthy controls. Representative test results
and/or mean ± SEM were depicted in the figures. For
statistical analysis PASW Statistics program version 21
(IBM, Chicago, Illinois, USA) and Wilcoxon (Figs. 3, 4
and 6a) and Student t test (Fig. 5) were used. P-values
≤0.05 were considered significant. P-values of 0.056
were considered to show a trend.
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